Immunome, Inc. (NASDAQ:IMNM) Receives $29.80 Consensus Target Price from Brokerages

Immunome, Inc. (NASDAQ:IMNM) has earned a consensus rating of “Buy” from the seven ratings firms that are presently covering the firm, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average 12 month price objective among brokers that have covered the stock in the last year is $29.80.

Several research firms recently commented on IMNM. Guggenheim began coverage on Immunome in a research note on Monday, April 15th. They set a “buy” rating and a $35.00 target price for the company. JPMorgan Chase & Co. began coverage on Immunome in a research note on Tuesday, April 30th. They set an “overweight” rating and a $24.00 target price for the company. Wedbush reissued an “outperform” rating and set a $33.00 target price on shares of Immunome in a research note on Tuesday, May 14th. Finally, Piper Sandler began coverage on Immunome in a research note on Friday, May 31st. They set an “overweight” rating and a $27.00 target price for the company.

Immunome Trading Up 0.3 %

IMNM stock opened at $15.20 on Tuesday. The company has a market capitalization of $911.53 million, a PE ratio of -2.01 and a beta of 1.85. Immunome has a 12-month low of $4.50 and a 12-month high of $30.96. The business’s fifty day moving average price is $16.20 and its 200 day moving average price is $16.40.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.46. Immunome had a negative return on equity of 37.33% and a negative net margin of 1,829.44%. The firm had revenue of $1.03 million for the quarter, compared to the consensus estimate of $4.00 million. Research analysts predict that Immunome will post -1.45 EPS for the current fiscal year.

Insider Buying and Selling at Immunome

In related news, Director Jean Jacques Bienaime acquired 2,000 shares of Immunome stock in a transaction on Tuesday, May 21st. The stock was purchased at an average cost of $13.57 per share, with a total value of $27,140.00. Following the purchase, the director now directly owns 9,615 shares in the company, valued at $130,475.55. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 8.60% of the stock is owned by company insiders.

Institutional Trading of Immunome

Several institutional investors and hedge funds have recently added to or reduced their stakes in IMNM. Cetera Investment Advisers purchased a new position in shares of Immunome during the 1st quarter worth approximately $3,038,000. Farallon Capital Management LLC purchased a new position in shares of Immunome during the 1st quarter worth approximately $14,660,000. Zimmer Partners LP purchased a new position in shares of Immunome during the 1st quarter worth approximately $1,851,000. California State Teachers Retirement System purchased a new position in shares of Immunome during the 1st quarter worth approximately $807,000. Finally, Janus Henderson Group PLC raised its stake in shares of Immunome by 10.6% during the 1st quarter. Janus Henderson Group PLC now owns 1,538,414 shares of the company’s stock worth $37,957,000 after buying an additional 146,943 shares in the last quarter. 44.58% of the stock is owned by hedge funds and other institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.